cas 369656-57-5|| where to buy (S)-5,6,7,8-Tetrahydroquinolin-8-amine

Product Name:(S)-5,6,7,8-Tetrahydroquinolin-8-amine

IUPAC Name:(8S)-5,6,7,8-tetrahydroquinolin-8-amine

Packing Unit	Available Stock	Price($)
CM145671-250mg	1-2 Weeks	ǠŸȋ
CM145671-1g	1-2 Weeks	ƚǠǠ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 369656-57-5 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:369656-57-5; Molecular Formula:C9H12N2; Melting Point:-; Smiles Code:N[C@H]1CCCC2=CC=CN=C12; Density:

: Catalog Number:CM145671; Molecular Weight:148.21; Boiling Point:277.3°C at 760 mmHg; MDL No:MFCD09955590; Storage:Store at 2-8°C.

: Tetrahydroquinolines; Tetrahydroquinoline is one of the most important simple nitrogen heterocycles, widely found in nature and in a variety of pharmacologically active compounds. Tetrahydroquinoline is an important structure for the synthesis of various biologically active derivatives.

: Mavorixafor; X4 Pharmaceuticals’ lead product candidate, Mavorixafor (X4P-001) has reached a significant milestone with the submission of a New Drug Application (NDA) to the U.S. FDA for the treatment of WHIM Syndrome on September 5. This marks an important step forward in the regulatory approval process for Mavorixafor and highlights its potential as a promising therapy for patients with WHIM Syndrome.
WHIM syndrome was named after four symptoms: Warts, Hypogammaglobulinemia, Infections, Myelokathexis. WHIM syndrome is a rare and difficult-to-diagnose primary immunodeficiency in which the body’s immune system does not function properly and has trouble fighting infections, especially respiratory, ear, and skin infections.
Mavorixafor is an investigational small-molecule CXCR4 antagonist. It allosterically blocks the overstimulation of the CXCL12/CXCR4 pathway, having the potential to improve immune cell trafficking and immunosurveillance. Mavorixafor was designated orphan drug status by both the U.S. and the EU, and previously granted Fast Track Designation and Breakthrough Therapy Designation by the FDA.